Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual [Table]
Material Terms of Trading Arrangement [Text Block]	ITEM 9B. OTHER INFORMATION. Entry into a Material Definitive Agreement. On February 28, 2026, the Company entered into a Related Party Unsecured Promissory Note (the “Note”) with Fang Family Fund, LLC – Series I (the “Holder”). The Holder is a “related person” within the meaning of Item 404(a) of Regulation S-K by virtue of being an affiliate of Richard Fang, a current member of the Board of Directors of the Company (the “Board”). Pursuant to the Related Party Transactions Policy of the Company (the “Policy”), the Audit Committee and other disinterested members of the Board approved the Note in accordance with the guidelines set forth in the Policy. The Note provides for principal of up to an aggregate of $0.7 million (the “Maximum Principal Amount”), and the Company received $0.7 million in proceeds from the Holder. Amounts outstanding under the Note bear interest at a fixed rate of 6.00% per annum, compounded annually. Interest is payable in kind on each quarterly anniversary of the Note’s date, although the Company may, at its option, pay interest in cash on any interest payment date. The outstanding principal and any accrued and unpaid interest are payable in cash on February 28, 2027 (the “Maturity Date”). The Company may, with the Holder’s written consent, extend the Maturity Date. The Company may prepay the Note at any time, in whole or in part, without premium or penalty. The Note requires mandatory prepayment upon the consummation by the Company or any subsidiary of a Qualified Financing, defined as an equity or equity-linked financing for aggregate gross proceeds to the Company of at least $5 million. Upon a Qualified Financing, the Company must prepay the then-outstanding principal together with all accrued and unpaid interest and other amounts due under the Note on the closing date of such financing or, if the Company retains proceeds sufficient to fund at least $2.0 million of post-closing working capital after payment of reasonable transaction fees and expenses, no later than the first Business Day following the Company’s receipt of the remaining proceeds. Mandatory prepayment is subject to any applicable intercreditor arrangements and is not intended to contravene any then-existing senior secured debt facility; the Company will use commercially reasonable efforts to obtain any required consents. The Note is unsecured and ranks pari passu in right of payment with all other unsubordinated, unsecured indebtedness of the Company. Events of default under the Note include failure to pay when due (subject to a 30-day cure period for nonpayment), dissolution or cessation of operations, and certain bankruptcy or insolvency events. The Note also includes customary information, inspection, confidentiality, and other provisions. The Company intends to use the net proceeds from the Note for short-term liquidity needs and other business expenses, including those that may be incurred in pursuing additional equity financing. The Note contains representations and warranties, affirmative and negative covenants, and events of default that the Company considers customary for an agreement of this type and on terms fair to, or no less favorable to, terms the Company than could have obtained in a comparable transaction with an unaffiliated party. The foregoing summary of the Note does not purport to be complete and is qualified in its entirety by reference to the full text of the Note, a copy of which is filed as Exhibit 10.59 to this Annual Report and incorporated herein by reference.
Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false

Picard Medical, Inc. 10-K